ReviewOncoTargets and therapy2015
Volasertib for AML: clinical use and patient consideration.
Review in OncoTargets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.Clinical pharmacokinetics · 2018Trial
- Multi-omics and single-cell approaches reveal molecular subtypes and key cell interactions in hepatocellular carcinoma.Frontiers in pharmacology · 2025Article
- The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas.Veterinary and comparative oncology · 2022Article
- Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.Journal of personalized medicine · 2022Review
- A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.Molecular cancer research : MCR · 2022Article
- Article
- Volasertib preclinical activity in high-risk hepatoblastoma.Oncotarget · 2019Article
- Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.Therapeutic advances in hematology · 2019Review
- Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice.PloS one · 2019Article
- Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.Current pharmaceutical design · 2017Review
- Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.Oncology reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.